What GLP-1 injections are currently available?

Currently available injectable GLP-1 medications include Wegovy and Ozempic (both semaglutide), and Zepbound and Mounjaro (both tirzepatide, a dual GLP-1/GIP receptor agonist). All are administered as weekly subcutaneous injections using a pre-filled pen.

Is there a GLP-1 pill I can take instead of injecting?

Yes. Oral semaglutide (the Wegovy pill) was FDA-approved for weight loss in December 2025 and launched in January 2026. It uses the same active molecule as injectable Wegovy but is taken as a daily tablet. Orforglipron, a non-peptide oral GLP-1, is also in late-stage development.

Can I switch from an injection to a pill?

Whether switching is appropriate depends on your current medication, dose, and clinical circumstances. This is a conversation to have with your prescribing clinician — they can advise on whether a switch is suitable and how to approach it safely.

GLP-1 articles · GLP-1 & weight-loss medications

Oral vs Injectable GLP-1: Which Is Right for You?

Q: What is orforglipron?

Orforglipron is a non-peptide oral GLP-1 receptor agonist in late-stage development, with a potential approval timeline around Q2 2026. Its non-peptide structure means it may not require the same strict fasting conditions as oral semaglutide.

Both oral and injectable GLP-1 medications activate the same receptor to reduce appetite and support weight loss — but they differ in dosing frequency, how they're absorbed, and what's currently available. This comparison covers the key practical differences to help you have an informed conversation with your clinician.

Jonathan Meagher · 28 June 2026 · 7 min read

Educational information only. This article does not diagnose, treat, cure or prevent any condition and is not medical advice. Whether a weight-loss medication is right for you, and decisions about starting, stopping or adjusting it, are a matter for you and your qualified healthcare professional.

What injectable GLP-1s are currently available?

Four injectable GLP-1-class medications are currently available for weight management or type 2 diabetes:

Wegovy (semaglutide) — approved for weight loss; weekly subcutaneous injection
Ozempic (semaglutide) — approved for type 2 diabetes, widely used off-label for weight management; weekly injection
Zepbound (tirzepatide) — dual GLP-1/GIP receptor agonist, approved for weight loss; weekly injection
Mounjaro (tirzepatide) — approved for type 2 diabetes; weekly injection

All four use a pre-filled pen device and are injected subcutaneously (under the skin) once a week.

What oral GLP-1s are available now?

As of early 2026, one oral GLP-1 is available:

Oral semaglutide (Wegovy pill) — FDA-approved for weight loss December 2025, launched January 2026. Same active molecule as injectable Wegovy, taken as a daily tablet with strict fasting and timing requirements.

A second oral option is in late-stage development: orforglipron, a non-peptide oral GLP-1 receptor agonist. It is not yet approved, with a potential timeline around Q2 2026.

How do oral and injectable GLP-1s compare?

The table below covers the key practical differences:

	Injectable GLP-1	Oral GLP-1 (pill)
Dosing frequency	Weekly injection	Daily tablet
Examples available	Wegovy, Ozempic, Zepbound, Mounjaro	Wegovy pill (semaglutide); orforglipron (coming ~2026)
Administration	Subcutaneous pen	Swallowed with water
Needle required	Yes	No
Consistency required	Weekly	Must be taken same time daily, fasted

Both formats work through the same GLP-1 receptor mechanism. Needle aversion is a real and valid consideration — for those who find injections difficult or distressing, the oral format removes a practical barrier. On the other hand, the daily fasting requirement for the pill demands consistent daily discipline that a once-weekly injection doesn't.

What is orforglipron and when is it coming?

Orforglipron is a non-peptide small-molecule oral GLP-1 receptor agonist currently in late-stage trials. Unlike oral semaglutide — which is a peptide and requires a special absorption enhancer plus strict fasting — orforglipron's non-peptide structure means it is absorbed differently and may not require the same food-timing restrictions.

Its potential approval timeline is around Q2 2026, subject to regulatory review. It is not yet approved or available. Talk to your clinician about what's accessible to you now and how the landscape may evolve.

Which format should I discuss with my clinician?

There is no universally better format. The right choice depends on individual factors including:

Your ability to consistently follow the oral dosing protocol (fasting, timing, water volume)
Whether needle aversion is a significant factor for you
What your prescriber has access to and is familiar with prescribing
Your existing medications and whether timing conflicts exist
Cost and insurance coverage in your system

Whichever format you use, the muscle-protection essentials remain the same: adequate protein, resistance training, and evidence-dosed support supplements. The GLP-1 mechanism — not the delivery format — is what drives the calorie deficit that puts lean mass at risk.